LEADER 01136cam0-22003371i-450- 001 990004464680403321 005 20140702090256.0 035 $a000446468 035 $aFED01000446468 035 $a(Aleph)000446468FED01 035 $a000446468 100 $a19990604d1921----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ab-------001yy 200 1 $a<>guerra alla fronte italiana fino all'arresto sulla linea della Piave e del Grappa$e(24 maggio 1915 - 9 novembre 1917)$fLuigi Cadorna 210 $aMilano$cFratelli Treves$d1921 215 $a2 v. (VIII, 307; 272 p.)$d24 cm 327 0 $a1 busta (3 c. geogr. ripieg.) 610 0 $aGuerra mondiale 1914-1918$aItalia 676 $a945.0913 676 $a940.44$v22$zita 700 1$aCadorna,$bLuigi$f<1850-1928>$0178163 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990004464680403321 952 $a940.44 CAD 1 (1)$bBibl. 7324$fFLFBC 952 $a940.44 CAD 1 (2)$bBibl. 7324$fFLFBC 959 $aFLFBC 996 $aGuerra alla fronte italiana fino all'arresto sulla linea della Piave e del Grappa$9545189 997 $aUNINA LEADER 04297nam 2200433 450 001 9910420949903321 005 20210219101713.0 010 $a3-030-53868-0 024 7 $a10.1007/978-3-030-53868-2 035 $a(CKB)4100000011457761 035 $a(DE-He213)978-3-030-53868-2 035 $a(MiAaPQ)EBC6355545 035 $a(PPN)250223368 035 $a(EXLCZ)994100000011457761 100 $a20210219d2020 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDamage-associated molecular patterns in human diseases$hVolume 2$iDanger signals as diagnostics, prognostics, and therapeutic targets /$fWalter Gottlieb Land 205 $a1st ed. 2020. 210 1$aCham, Switzerland :$cSpringer,$d[2020] 210 4$dİ2020 215 $a1 online resource (XXXIX, 629 p. 45 illus. in color.) 311 $a3-030-53867-2 327 $aPart I. Prologue -- Perspectives of the Danger/Injury Model in Immunology -- Part II. A Select, Clinically Oriented Update of Topics Presented in ?Damage-Associated Molecular Patterns in Human Diseases?; Volume 1: Injury-Induced Innate Immune Responses -- Pattern Recognition Molecules -- The Growing World of DAMPs -- The Growing Clinical Relevance of Cellular Stress Responses and Regulated Cell Death -- DAMP-Promoted Efferent Innate Immune Responses in Human Diseases: Inflammation -- DAMP-Promoted Efferent Innate Immune Responses in Human Diseases: Fibrosis -- Part III. DAMPs and SAMPs in Traumatic Disorders, Atherosclerosis, and Cerebro-Cardiovascular Diseases -- DAMPs and SAMPs as Molecular Biomarkers, Therapeutic Targets, and Therapeutics -- DAMP-Controlled and Uncontrolled Responses to Trauma: Wound Healing and Polytrauma -- Solid Organ Injury -- Atherosclerosis -- Cerebro - Cardiovascular Diseases -- Part IV. Epilogue -- The ?DAMPome? as a Key Player in the Pathogenesis of Human Diseases. 330 $aThis book is a continuance of the topic: ?DAMPs in Human Diseases?, the basics of which were described in a first volume by the same author. This second volume presents our current understanding of the impact of sterile stress/injury-induced innate immune responses on the etiopathogenesis of human diseases by focusing on those diseases that are pathogenetically dominated by DAMPs, i.e., on polytrauma, various solid organ injuries (brain, lung, kidney, liver), atherosclerosis, and cerebro-cardiovascular diseases. Our growing understanding of the pathogenetic function of activating DAMPs and suppressive DAMPs (?SAMPs?) is used as a point of departure to explore how these molecules can be used as biomarkers to extend and improve current diagnostic and prognostic modalities. Moreover, this new knowledge about the pathogenetic function of DAMPs and SAMPs is taken as a sound and plausible reason for discussing their implications for present and future treatment of the diseases addressed here. In this context, the focus is on the potential of DAMPs as future therapeutic targets and SAMPs as future therapeutics, applied in strict compliance with safety precautions, as also recommended in this work. The book is intended for professionals from all medical and paramedical disciplines who are interested in applying innovative data from inflammation and immunity research to clinical practice. The readership will include practitioners and clinicians working in the broad field of acute and chronic inflammatory/fibrotic diseases, in particular, traumatologists and intensivists; neurologists and neurosurgeons; cardiologists and cardiac surgeons; pulmonologists and thoracic surgeons; vascular surgeons; nephrologists; gastroenterologists and hepatologists; and pharmacists. Also available: Damage-Associated Molecular Patterns in Human Diseases - Vol. 1: Injury-Induced Innate Immune Responses . 606 $aWounds and injuries$xImmunological aspects 615 0$aWounds and injuries$xImmunological aspects. 676 $a617.1 700 $aLand$b W$g(Walter),$0909257 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910420949903321 996 $aDamage-associated molecular patterns in human diseases$92034040 997 $aUNINA LEADER 04829oam 2200769 450 001 9910716079603321 005 20220513104357.0 035 $a(CKB)5470000002517306 035 $a(OCoLC)814440675$z(OCoLC)1118520349 035 $a(EXLCZ)995470000002517306 100 $a20120913d2012 ua 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aShared medical appointments for chronic medical conditions $ea systematic review /$fDavid Edelman [and six others] 210 1$aWashington, DC :$cDepartment of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service,$d2012. 215 $a1 online resource (iii, 72 pages) $cillustrations 300 $a"Evidence-based synthesis program." 300 $a"July 2012." 320 $aIncludes bibliographical references. 330 3 $aThe most successful health care systems offer ready access to high-quality primary care--an approach that is embedded in the fundamental design of Veterans Affairs (VA) health care and which is consistent with the Institute of Medicine's definition of high-quality care. This definition emphasizes safe, effective, patient-centered, timely, efficient, and equitable health care. Group medical visits are a method to deliver health care that offers the promise of improving these aspects for patients with chronic conditions.^Group visits (or clinics) are a system redesign in which clinicians see multiple patients together in the same clinical setting.^Shared medical appointments (SMAs) are a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state.^SMAs usually involve both a person trained or skilled in delivering patient education or facilitating patient interaction and a practitioner with prescribing privileges. SMA sessions typically last 60 to 120 minutes, with time set aside for social integration, interactive education, and medication management, in an effort to achieve improved disease outcomes. SMAs have been scientifically tested in an array of primary care settings over the last 10 to 15 years.^However, there has been great variability among these studies in relation to setting; components included in the intervention; and measurement of clinical, cost, and utilization outcomes.^For example, the patient group may stay constant, in an attempt to provide group bonding, or the patients may be allowed to choose sessions from a schedule at their convenience to promote attendance. Like patients, provider teams can be constant or vary over time.^This uncertainty regarding the optimal design and impact of SMAs led the VA to commission this evidence synthesis report. Our objective was to summarize the effects of SMA on staff, patient, and economic outcomes and to evaluate whether the impact varied by clinical condition or specific intervention components. 517 $aShared medical appointments for chronic medical conditions 606 $aGroup medical appointments$zUnited States 606 $aChronic diseases$xTreatment$zUnited States 606 $aChronically ill$zUnited States 606 $aOutcome assessment (Medical care)$zUnited States 606 $aMedical appointments and schedules 606 $aChronic diseases$xTreatment$2fast 606 $aChronically ill$2fast 606 $aGroup medical appointments$2fast 606 $aOutcome assessment (Medical care)$2fast 607 $aUnited States$2fast 608 $aTechnical reports.$2lcgft 615 0$aGroup medical appointments 615 0$aChronic diseases$xTreatment 615 0$aChronically ill 615 0$aOutcome assessment (Medical care) 615 0$aMedical appointments and schedules. 615 7$aChronic diseases$xTreatment. 615 7$aChronically ill. 615 7$aGroup medical appointments. 615 7$aOutcome assessment (Medical care) 700 $aEdelman$b David A.$0320843 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aDurham VA Medical Center.$bEvidence-based Synthesis Program Center. 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bNLM 801 1$bNLM 801 2$bOCLCQ 801 2$bVT2 801 2$bNLM 801 2$bOCLCO 801 2$bOCLCA 801 2$bGPO 801 2$bOCLCO 801 2$bOCLCF 801 2$bOCLCQ 801 2$bOCLCO 801 2$bCOM 801 2$bOCLCO 801 2$bGPO 906 $aBOOK 912 $a9910716079603321 996 $aShared medical appointments for chronic medical conditions$93470597 997 $aUNINA